Healthcare Economist

Jason Shafrin, PhD, describes 6 key steps to implementing distributional cost-effectiveness analysis.

Jason Shafrin, PhD, discusses a report from the Health Care Payment Learning and Action Network which assessed whether alternative payment models have gained market share from 2019 to 2020.

Jason Shafrin, PhD, discusses a survey which explored affordability challenges posed by orphan drugs from the payer, provider, and employer perspectives.

Jason Shafrin, PhD, discusses the effect quality impacts during COVID-19 will have on Medicare reimbursement to providers through 2024.

Jason Shafrin, PhD, highlights the Patient-Centered Outcomes Research Institute's (PCORI) Proposed “Principles” for the Consideration of the Full Range of Outcomes Data.

Jason Shafrin, PhD, highlights a study noting that value assessment is not a one-time endeavor but needs to be revisited as a treatment landscape evolves.

Jason Shafrin, PhD, provides commentary on why value-based agreements will likely never make up the majority of drug reimbursement.